Comparative Pharmacology
Head-to-head clinical analysis: BREVIBLOC IN PLASTIC CONTAINER versus METOPROLOL TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVIBLOC IN PLASTIC CONTAINER versus METOPROLOL TARTRATE.
BREVIBLOC IN PLASTIC CONTAINER vs METOPROLOL TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Esmolol is a cardioselective beta-1 adrenergic receptor antagonist with minimal intrinsic sympathomimetic activity and membrane-stabilizing properties. At therapeutic doses, it blocks beta-1 receptors in the myocardium, decreasing heart rate, myocardial contractility, and AV conduction velocity, leading to reduced cardiac output and myocardial oxygen demand.
Competitive beta-1 adrenergic receptor antagonist with weak beta-2 blocking activity; reduces heart rate, contractility, and AV conduction.
Initial loading dose: 500 mcg/kg IV over 1 minute, followed by continuous IV infusion of 50 mcg/kg/min for 4 minutes; if inadequate response, repeat loading dose and increase infusion by 50 mcg/kg/min increments up to 200 mcg/kg/min. Maintenance: 25-200 mcg/kg/min continuous IV infusion.
Initial dose 100 mg daily in divided doses (e.g., 50 mg twice daily) orally; may increase weekly up to 200-450 mg daily in 2-3 divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 9 minutes (range 4–15 minutes) for the parent drug, leading to rapid offset of effect. The half-life of the metabolite ASL-8123 is about 3.7 hours.
3–4 hours (terminal) in healthy adults; prolonged to 7–8 hours in severe hepatic impairment; no change in renal impairment.
Elimination primarily via red blood cell esterases; renal excretion of unchanged drug is less than 1% of dose. Metabolite ASL-8123 is inactive and renally excreted.
Renal: 95% as metabolites, <5% unchanged. Fecal: negligible.
Category C
Category C
Beta-Blocker
Beta-Blocker